/
MGNX
$4.86+$0.05 (+1.04%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$305.7M
64M shares
52-week range
$1.19 – $5.08
94% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.42%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-23.33
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $60.1M | $62.0M | $97.8M | $75.6M | $150.0M | $57.2M | $148.3M | $149.5M |
| Cost of revenue | $0 | $0 | $0 | $2.7M | $7.4M | $8.2M | $12.3M | $43.2M |
| Gross profit | $60.1M | $62.0M | $97.8M | $73.0M | $142.6M | $49.0M | $136.0M | $106.3M |
| Gross margin | 100.0% | 100.0% | 100.0% | 96.5% | 95.1% | 85.6% | 91.7% | 71.1% |
| R&D | $190.8M | $195.3M | $193.2M | $214.6M | $207.0M | $166.6M | $177.2M | $140.0M |
| Operating income | −$171.2M | −$177.2M | −$131.1M | −$202.8M | −$121.4M | −$168.2M | −$110.6M | −$72.8M |
| EBITDA | −$162.0M | −$164.9M | −$119.1M | −$190.9M | −$107.9M | $2.0M | −$57.4M | −$59.6M |
| Net income | −$171.5M | −$151.8M | −$129.7M | −$202.1M | −$119.8M | −$9.1M | −$67.0M | −$74.6M |
| Net margin | -285.2% | -244.8% | -132.7% | -267.2% | -79.8% | -15.8% | -45.1% | -49.9% |
| EPS (diluted) | -4.19 | -3.16 | -2.25 | -3.18 | -1.95 | -0.15 | -1.07 | -1.18 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $152M | $-0.91 | $-1.46–$-0.34 | 3 |
| 2027 | $103M | $-1.23 | $-1.59–$-0.87 | 3 |
| 2028 | $172M | $-1.29 | $-2.19–$-0.64 | 3 |
| 2029 | $226M | $-0.86 | $-1.25–$-0.47 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
MacroGenics, Inc.
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.
www.macrogenics.com- Employees
- 293
- IPO / List date
- Oct 10, 2013
- HQ
- Rockville, MD
Held by traders on TradeandTell
No one on the platform currently holds MGNX.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 2,963,559 | $8.6M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded MGNX yet.
